galecto.com

Galecto Biotech

Galecto Biotech's email is hs@galecto.com .

Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, in which there is high unmet medical need. Galecto was founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with ...

read more

Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, in which there is high unmet medical need. Galecto was founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.

show less

View Top Employees for Galecto Biotech
img Website galecto.com
img Industry Biotechnology
img Location Denmark
img Employees 27
img Founded 2011
img HQ Cobis Science Park Ole Maaloes Vej 3
img Email hs@galecto.com
img Funding 160,412,604 USD
img Competitors Roche, Agilent Technologies, Amgen, Genentech, Eurofins, Gilead Sciences,
img Website galecto.com
img Industry Biotechnology
img Location Denmark
img Employees 27
img Founded 2011
img LinkedIn linkedin.com/company/galecto-biotech
img HQ Cobis Science Park Ole Maaloes Vej 3
img Email hs@galecto.com
img Funding 160,412,604 USD

Top Galecto Biotech Employees